Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04313140

Virtual Biopsy Development to Identify Patient's Glioma Grade at the CHU of Poitiers Using Magnetic Resonance Imaging

Glioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help to define the most adapted treatment.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Development of the Virtual Biopsy Artificial Intelligence Algorithms Clinical Radiological Tumor Grade

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age≥ 18 years,
  • Patient with suspected glioma with prior imaging
  • Subject free, with legal protection guardianship or curatorship;
  • Enrollment in the French Social Security system;
  • Informed consent signed by the patient

Exclusion criteria

  • Any contraindication to an MRI examination
  • Legal protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons residing in a health or social establishment, adults under legal protection and finally patients in emergency situations
  • Pregnant or lactating women, women of childbearing age who do not have effective contraception

Treatment and study plan

Diagnostic Test

Diagnostic Test

The intervention occurs only one time (for 2h30), the MRI examination is divided as follow:

  • Cinicial MRI (50 minutes)
  • Research MRI (Phosphorus Spectroscopy, Sodium Imaging)

Primary outcomes

  1. Validation of the virtual biopsy in the context of gliomas through the use of statistical learning algorithms (artificial intelligence) compared to the biopsy.

    Time frame: The MRI examination (for 2 hours 30 minutes)

    Evaluate the diagnostic capabilities of artificial intelligence algorithms for virtual biopsy based on sensitivity and specificity

Study contacts

Contact information is provided by the study sponsor or research team.

Rémy GUILLEVIN, Pr

CONTACT

[email protected]

05.49.44.45.42

Sponsors and collaborators

Lead sponsor

Poitiers University Hospital

Other

Registry information

Acronym: MR3TGLIOBIOPSY

Important dates

Study start
2021
Primary completion
2029
Study completion
2029
First posted
Mar 18, 2020
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.